Loukas Thanos
National and Kapodistrian University of Athens
76 Papers
580 Citations
Loukas Thanos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Radiofrequency ablation & Medicine. The author has an hindex of 20, co-authored 74 publications.
Chat about Author
Papers
Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma
TL;DR: Radiofrequency (RFA) and microwave ablation (MWA) are among the therapeutic modalities, with similar indications which include the presence of up to three lesions, smaller than 3 cm in size, and the absence of extrahepatic disease.
314
Radiofrequency ablation of osseous metastases for the palliation of pain.
Loukas Thanos,Sofia K. Mylona,Panagiota Galani,D. Tzavoulis,V. Kalioras,S. Tanteles,Maria Pomoni +6 more
TL;DR: CT-guided radiofrequency (RF) ablation appears to be effective for treatment of painful bone metastases and the use of analgesics decreased.
FDG PET Is a Robust Tool for the Diagnosis of Spondylodiscitis: A Meta-analysis of Diagnostic Data
Michael L. Prodromou,Panayiotis D. Ziakas,Loukia S. Poulou,Petros Karsaliakos,Loukas Thanos,Eleftherios Mylonakis +5 more
TL;DR: FDG PET is a robust diagnostic test when spondylodiscitis is suspected and is excellent for exclusion of infectious spondylon disease given its low likelihood ratio negative (<0.1).
63
Osteoid osteomas in common and in technically challenging locations treated with computed tomography-guided percutaneous radiofrequency ablation.
Sophia Mylona,Sofia Patsoura,Panagiota Galani,Georgios Karapostolakis,Anastasia Pomoni,Loukas Thanos +5 more
TL;DR: CT-guided RF ablation is safe and highly effective for treatment of osteoid osteomas, even in technically difficult positions.
57
Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials
TL;DR: The predictive value of 18F-FDG PET in patients with relapsing/refractory lymphoma who are receiving high-dose chemotherapy and autologous stem cell transplantation (ASCT) remains a matter of debate.
51